Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Trinity Biotech ( (TRIB) ) has issued an update.
On May 14, 2025, Trinity Biotech and its subsidiaries amended and restated their credit agreement with Perceptive Credit Holdings III, L.P. The following day, the company announced its fourth quarter and fiscal year 2024 financial results, alongside a business update, indicating strategic financial adjustments and providing stakeholders with insights into its operational performance.
Spark’s Take on TRIB Stock
According to Spark, TipRanks’ AI Analyst, TRIB is a Underperform.
Trinity Biotech’s stock score is low due to significant financial difficulties, including declining revenues and high leverage. Technical indicators suggest a downtrend with potential overbought conditions. Although the earnings call noted some improvements, persistent challenges and a negative valuation outlook weigh heavily on the overall score.
To see Spark’s full report on TRIB stock, click here.
More about Trinity Biotech
Trinity Biotech is a company based in Ireland, operating in the biotechnology industry. It focuses on developing and manufacturing diagnostic products for clinical laboratories, hospitals, and healthcare providers.
Average Trading Volume: 65,223
Technical Sentiment Signal: Sell
Current Market Cap: $8.6M
Learn more about TRIB stock on TipRanks’ Stock Analysis page.